<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002817</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000064975</org_study_id>
    <secondary_id>JMC-94-0843</secondary_id>
    <secondary_id>NCI-H96-0965</secondary_id>
    <nct_id>NCT00002817</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Metastatic Melanoma</brief_title>
  <official_title>INTRALESIONAL IMMUNOTHERAPY WITH A VACCINIA/GM-CSF RECOMBINANT VIRUS IN PATIENTS WITH METASTATIC MELANOMA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Cancer Center at Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines may make the body build an immune response to kill melanoma cells.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients&#xD;
      with metastatic melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the toxicity of intralesional immunotherapy with a recombinant&#xD;
      vaccinia virus encoding the gene for sargramostim (GM-CSF) in patients with metastatic&#xD;
      melanoma. II. Determine the efficiency of viral infection and GM-CSF gene insertion and&#xD;
      function in these patients. III. Determine the capacity of this regimen to generate antiviral&#xD;
      and antitumor immunity in these patients. IV. Determine the frequency of regression of&#xD;
      injected and uninjected lesions in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of intralesional recombinant vaccinia virus encoding&#xD;
      the gene for sargramostim (GM-CSF) (rV-GM-CSF). Patients are stratified by center. Patients&#xD;
      receive small pox (vaccinia) vaccine via multipuncture technique on day 0. On day 4, patients&#xD;
      with a progressive major reaction to the initial vaccination receive rV-GM-CSF&#xD;
      intralesionally twice weekly for 5 weeks. Only 1 lesion is treated and at least 1 measurable&#xD;
      lesion is left untreated in each patient. Patients with responding disease after week 5 are&#xD;
      retreated at a clinically appropriate dose and schedule. Cohorts of 5 patients receive&#xD;
      escalating doses of intralesional rV-GM-CSF until the maximum tolerated dose (MTD) is&#xD;
      determined. Additional patients receive rV-GM-CSF at the MTD.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 30 patients (15 for each phase) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 1996</start_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>vaccinia-GM-CSF vaccine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven melanoma that is considered surgically&#xD;
        incurable Dermal, subcutaneous, or lymph node metastases required At least 3 lesions&#xD;
        evaluable and accessible for injection and biopsy One lesion at least 10 mm in diameter No&#xD;
        leukemia or lymphoma&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 Life expectancy: At&#xD;
        least 6 months Hematopoietic: Not specified Hepatic: Bilirubin no greater than 3 times&#xD;
        upper limit of normal (ULN) SGOT no greater than 3 times ULN Alkaline phosphatase no&#xD;
        greater than 3 times ULN Renal: Creatinine no greater than 3 times ULN Immunologic:&#xD;
        Clinical evidence of immune response required within 4 days of smallpox vaccination At&#xD;
        least 1 positive cutaneous delayed-type hypersensitivity response to 1 of the following:&#xD;
        Microbial recall antigens Dinitrofluorobenzene after sensitization Purified protein&#xD;
        derivative of tuberculin following BCG vaccination No altered immunocompetence (e.g.,&#xD;
        immune deficiency disease or immunosuppressive therapy) in patient or household contacts No&#xD;
        allergy to any of the following: Polymyxin B sulfate Streptomycin sulfate Chlortetracycline&#xD;
        hydrochloride Neomycin sulfate No history of eczema or other exfoliative skin conditions in&#xD;
        patient or household contacts HIV negative Other: No other malignancy within the past 3&#xD;
        years except superficial squamous cell or basal cell skin cancer or carcinoma in situ of&#xD;
        the cervix or prostate Not pregnant or nursing Negative pregnancy test Fertile patients&#xD;
        must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 8 weeks&#xD;
        since prior chemotherapy No concurrent chemotherapy Endocrine therapy: No concurrent or&#xD;
        imminent steroid therapy Radiotherapy: At least 8 weeks since prior radiotherapy No&#xD;
        concurrent radiotherapy Surgery: See Disease Characteristics At least 4 weeks since prior&#xD;
        surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael J. Mastrangelo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sidney Kimmel Cancer Center at Thomas Jefferson University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kimmel Cancer Center of Thomas Jefferson University - Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107-5541</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2002</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 21, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2004</study_first_posted>
  <last_update_submitted>January 9, 2014</last_update_submitted>
  <last_update_submitted_qc>January 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2014</last_update_posted>
  <keyword>stage III melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

